PCVX

55.3355.18%
CV

Carlos V. Paya

Chair of the Scientific Advisory Board

Dr. Carlos V. Paya, M.D., Ph.D., serves as an Independent Director at Collegium Pharmaceutical, Inc. since May 15, 2025. He served as Head of R&D at Launch Therapeutics Inc. until 2025 and serves as its Advisor from 2025. He served as Interim Head of R&D at Launch Therapeutics inc. He serves as Independent Chairman of the Board and Director at Vaxcyte, Inc. since October 2021. He serves as the Venture Partner at Ysios Capital Partners, SGEIC, S. A.U. since joining in June 2020. He served as Chairman of the Board at Highlight Therapeutics, S. L. since March 2020 until April 17, 2020 and serves as its Executive Chairman since April 17, 2020. He supports the evaluation of potential investments and advise the team with respect to investment decisions. He serves as a Venture Partner at Abingworth LLP. He experts in Clinical Co-Development, Venture. The Carlyle Group since January 2020 and has served as the Acting Head of R&D at Launch Therapeutics since April 2022. Prior, he was Senior Advisor at the firm. He is an expert in Immunology and infectious diseases. Dr. Paya has a distinguished track record of leadership in large-cap pharma and mid-cap biotech and start-up companies, with a focus on strategic execution, pipeline growth, product life cycle management and global product launches, as well as a number of successful public and private fundraises. He serves as a Director of Highlight Therapeutics S. L. since April 2020. He serves as Chair of the Scientific Advisory Board at Sutro Biopharma, Inc since May 2020. He had been Independent Director of Mallinckrodt Pharmaceuticals plc since May 22, 2019 until June 2022. He has been Chairman of the Board at Standard BioTools Inc. (formerly known as Fluidigm Corporation) since June 2020 and its Independent Director since March 2017. He was the Chief Executive Officer and President of Immune Design Corp. since May 2, 2011 until April 02, 2019 and served as its Director. He previously served as President of Elan Corporation, a pharmaceutical corporation from November 2008 to April 2011. Dr. Paya served as the President at Elan Pharmaceuticals Corp. plc since November 25, 2008 until 2011. He held leadership roles at Elan Pharmaceuticals and Eli Lilly and Co. in discovery research and clinical development. Dr. Paya led the Biotechnology commercial, marketing, clinical, research and development teams since 2008. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company, from September 2001 to November 2008, as Vice President, Lilly Research Laboratories and Global Leader of the Diabetes and Endocrine Platform, responsible for its dominant franchise (insulin products). He served as an Executive with Lilly since 2001, gaining a wide range of leadership experience in different therapeutic areas and business strategy. His therapeutic responsibilities have included infectious disease, inflammation, women's health and pulmonary; and his management responsibilities have included regulatory, joint venture relationships, pharmaco-economics, brand development and product positioning. Dr. Paya has several years of senior executive experience in the large, mid-cap and small-cap biopharmaceutical industries, combined with a prolific scientific background and a track record of leading high-impact innovation. Prior to his Executive career at Lilly, Dr. Paya had a unique, several-year relationship with the Mayo Clinic in Rochester, Minnesota, which began with his acceptance into the Mayo Graduate School of Medicine in 1984. Prior to his industry roles, Dr. Paya spent nearly a decade at the Mayo Clinic-Rochester, including as professor of medicine, immunology and pathology. He served as Vice Dean of the Clinical Investigation program at Mayo ClinInc. for six years. Dr. Paya's other responsibilities and positions with Mayo included two years as Senior Associate Consulting Staff, Infectious Diseases and Internal Medicine, Pathology and Laboratory Medicine and Immunology; and four years as a Research Scientist at Institute Pasteur, Paris and as Chief, Infectious Diseases Unit, Hospital 12 Octubre, Madrid, Spain. Dr. Paya was assisted in the search and hiring process for the position by Heidrick & Struggles. Dr. Paya had been a Director of Immune Design Corp. since May 2, 2011 until April 02, 2019. From January 1991 to August 2001, Dr. Paya was a Professor of Medicine, Immunology and Pathology at Mayo Clinic from 1991 to 2001. He was Associate Professor of Mayo for two years. He received his M. D. and Ph. D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur in Paris. Dr. Paya completed his specialty training in Internal Medicine, Infectious Diseases and Immunology at the Mayo Graduate School of Medicine. He completed the advanced management program at the University of Chicago's Booth School of Business.

Positions